Welcome to our dedicated page for FEMASYS news (Ticker: FEMY), a resource for investors and traders seeking the latest updates and insights on FEMASYS stock.
Femasys Inc. develops biomedical products for women’s reproductive health, with news centered on fertility treatment, fallopian tube assessment, and non-surgical permanent birth control. Its portfolio includes FemaSeed intratubal insemination, FemaSeed Complete for in-office fertility care, FemVue for ultrasound-based fallopian tube evaluation, FemBloc permanent birth control, and related diagnostic products such as FemChec.
Recurring updates cover product commercialization in OB/GYN settings, international distribution and market access, regulatory approvals outside the United States, U.S. clinical and regulatory development for FemBloc, reimbursement-related developments, financing, operating results, and governance changes.
Femasys (NASDAQ: FEMY) reported results for the quarter ended March 31, 2026, highlighting early commercial adoption of FemaSeed Complete, initiation of the FINALE pivotal trial for FemBloc, new international distribution partnerships, and leadership additions.
Financials: Q1 sales $424,889 (+24.5% YoY), R&D -55.9% to $1.31M, net income of $846,100, cash ~$5.4M expected to fund operations into Q3 2026, accumulated deficit ~$145.0M.
Femasys (NASDAQ: FEMY) announced the first revenue-generating commercial use of its fertility portfolio in the OBGYN setting on May 5, 2026, deploying FemaSeed as a first-line infertility treatment with supporting FemSperm for in-office sperm preparation.
The company says this enables earlier, lower-cost, in-office fertility care within routine OB/GYN practice and follows earlier-than-expected U.S. FDA clearance and clinical validation of FemaSeed.
Femasys (NASDAQ: FEMY) announced the commercial launch of FemaSeed Complete on April 22, 2026, a fertility solution enabling OB/GYNs to perform first-line insemination entirely in-office.
The product targets expanded access: an estimated 10 million U.S. women with infertility, leverage of >b>40,000 OB/GYNs versus fewer than 2,000 infertility specialists, and will be showcased at ACOG May 1–3, 2026.
Femasys (NASDAQ: FEMY) announced a strategic partnership with AMI Technologies to commercialize its fertility portfolio in Israel on April 16, 2026. The collaboration will introduce FemaSeed as a first-line infertility treatment and deploy FemVue for ultrasound diagnosis of tubal factors, leveraging AMI’s local commercial infrastructure to accelerate physician adoption.
This move aims to expand international market access, increase physician awareness across key fertility centers, and support broader patient access to non-surgical fertility solutions.
Femasys (NASDAQ: FEMY) appointed John Canning as Chief Operating Officer effective April 1, 2026. Mr. Canning brings over 25 years of medical device operations and technology leadership to support commercialization of FemBloc and FemaSeed.
The company granted a 150,000-share inducement option, vesting 25% after one year and quarterly annual vesting thereafter, approved under Nasdaq Listing Rule 5635(c)(4).
Femasys (NASDAQ: FEMY) reported 2025 results and corporate progress on March 31, 2026. Sales rose 40.8% to $2,293,313, driven by FemBloc, while net loss was $18,627,887 (−$0.47 per share). Cash and cash equivalents were approximately $9.3 million, expected to fund operations into Q3 2026.
Key operational milestones include initiation of patient enrollment in the FINALE pivotal trial for FemBloc, FDA 510(k) clearance for FemVue, MDSAP certification for FemBloc, AMA Category III CPT code for FemaSeed, a $12 million financing, and a Switzerland distribution partnership.
Femasys (NASDAQ: FEMY) appointed Dr. Kenneth D. Eichenbaum to its board on March 18, 2026. Dr. Eichenbaum is a board-certified anesthesiologist with over 20 years evaluating biotech and medical device companies, and holds degrees from Icahn School of Medicine, University of Pennsylvania, and Wharton.
The company thanked Joshua Silverman for his board service and highlighted Dr. Eichenbaum’s clinical, engineering, and finance expertise as strategic support for Femasys’ growth in women’s reproductive health.
Femasys (NASDAQ: FEMY) has begun patient enrollment in the FDA-authorized FINALE pivotal trial of FemBloc, a first-of-its-kind non-surgical permanent birth control. The move follows an FDA Investigational Device Exemption approval and positive earlier clinical data. FemBloc is already approved and commercialized in Europe and select countries outside the U.S., and completion of FINALE is expected to support a future U.S. regulatory submission.
Femasys (NASDAQ: FEMY) announced that its FemBloc permanent birth control system achieved MDSAP certification on Feb. 26, 2026, enabling accelerated regulatory and commercial execution across the United States, Canada, Japan, Australia, and Brazil. The certification supports pivotal trial readiness toward a future PMA submission and strengthens manufacturing credibility for global expansion.
Femasys (NASDAQ: FEMY) received AMA CPT Editorial Panel approval for a new, unique Category III CPT code covering FemaSeed intratubal insemination (ITI). The code is expected to be issued publicly with an effective date of January 1, 2027.
This coding approval advances the company’s U.S. reimbursement strategy to support broader clinical adoption, provider rollout with the FemSperm product line, and expanded patient access; FemaSeed’s pivotal trial (NCT0468847) showed >2x pregnancy rates versus IUI. FemaSeed is authorized for use in the U.S., Europe, UK, Canada, and Israel.